Anavex Life Sciences Stock Price - AVXL

0.00 (0.0%)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Anavex Life Sciences Corporation AVXL NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 2.82 0.00 0.00 0.00 2.82 04:00:00
Bid Price Ask Price Spread Spread % News
1.50 3.57 2.07 57.98% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.82 USD

Anavex Life Sciences Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 165.44M 58.66M $ -17.45M -0.53 - 48.53M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Anavex Life Sciences News

Loading Messages....

Latest AVXL Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AVXL Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.883.462.6753.011,200,452-0.06-2.08%
1 Month4.144.442.202.921,201,402-1.32-31.88%
3 Months2.936.312.203.761,322,466-0.11-3.75%
6 Months3.156.312.203.40884,396-0.33-10.48%
1 Year2.966.312.203.31647,557-0.14-4.73%
3 Years5.756.491.253.43456,041-2.93-50.96%
5 Years8.5514.83991.254.64786,143-5.73-67.02%

Anavex Life Sciences Description

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company operating in the United States. It is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer's disease, other central nervous systems (CNS) diseases, pain and several types of cancer. The lead compound of the company is ANAVEX 2-73 which is developed to treat Alzheimer's disease, Parkinson's disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome. The research and development pipeline of the company includes one clinical drug candidate and several compounds in various stages of the pre-clinical study.

Your Recent History
Anavex Lif..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.